Trial | NCT02177370  Report issue

Title

Effect on Fenoterol Metered Dose Inhaler on the Beta-receptor Population on Lymphocytes in Patients With Bronchial Asthma
Effect of Fenoterol Metered Dose Inhaler (0.1 mg) on the Beta-receptor Population on Lymphocytes and the Clinical Findings Compared With Treatment With DSCG Metered Dose Inhaler in Patients With Bronchial Asthma.

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Terminated

  • Study Participants

    19
The aim of the study was to compare the effect of fenoterol metered dose inhaler with disodium cromoglycate (DSCG) metered dose inhaler on the lymphocyte β2-receptor population as well as on the clinical findings in patients with bronchial asthma over a two-week period of treatment.
Study Started
Feb 28
1990
Primary Completion
Oct 31
1996
Last Update
Jul 18
2014
Estimate

Drug Fenoterol MDI

Drug DSCG MDI

Fenoterol metered dose inhaler (MDI) Experimental

DSCG MDI Active Comparator

Criteria 

Inclusion Criteria:

sex: male and female
age: 18 years or over
bronchial asthma, diagnosis confirmed by history and positive inhalation challenge test (unspecific challenge with carbachol, PD100SRaw))
severity of asthma mild to moderate or asthmatic in symptom-free intervals
Raw ≤ 5 cm H2O/l/s
no antiasthmatic treatment in the week (steroid therapy: two weeks) before the start of the study

Exclusion Criteria:

clinically significant, concomitant haematological, cardiac, renal, hepatic or metabolic diseases
intercurrent diseases, e.g. severe respiratory infections

patients who cannot do without the following preparations during the 5-week trial:

inhaled/oral steroids
theophylline
antihistamine, antiallergic drugs
inhaled/oral sympathomimetics
anticholinergics
No Results Posted